The 10-second takeaway
For the quarter ended March 31 (Q1), Auxilium Pharmaceuticals whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped. Non-GAAP loss per share expanded. GAAP loss per share grew.
Margins shrank across the board.
Auxilium Pharmaceuticals reported revenue of $66.2 million. The 10 analysts polled by S&P Capital IQ looked for net sales of $82.1 million on the same basis. GAAP reported sales were 10% lower than the prior-year quarter's $73.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.12. The six earnings estimates compiled by S&P Capital IQ anticipated $0.03 per share. Non-GAAP EPS were -$0.12 for Q1 compared to -$0.04 per share for the prior-year quarter. GAAP EPS were -$0.17 for Q1 versus -$0.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 77.2%, 20 basis points worse than the prior-year quarter. Operating margin was -7.7%, 510 basis points worse than the prior-year quarter. Net margin was -12.4%, 1,000 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $92.2 million. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $377.3 million. The average EPS estimate is $0.31.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 135 members out of 189 rating the stock outperform, and 54 members rating it underperform. Among 53 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give Auxilium Pharmaceuticals a green thumbs-up, and 23 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $21.80.
- Add Auxilium Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.